메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

HSI Donesafe and Neopharma Technologies Announce A…

SYDNEY, Feb. 24, 2026 -- Many organisations have invested heavily in safety management systems, yet Fit-For-Duty controls are still handled separately or measured inconsistently. Drug and alcohol programs often sit outside core safety platforms, while functional impairment from fatigue, illness, stress, or psychosocial hazards is rarely assessed routinely or recorded in a consistent, auditable way. HSI Donesafe and Neopharma Technologies Ltd today announced a partnership to close this gap by embedding Fit-For-Duty workflows directly into the Donesafe platform.&nbs
- 김갑성 기자
- 2026-02-24 09:10
ZEISS launches Collaborative Care application to strengthen…

Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate – whether as a standalone cloud application or as an integrated extension of ZEISS FORUM – enabling secure data sharing, structured referrals, and real-time clinical coordination to strengthen continuity of care across the ophthalmic workflow. JENA, Germany, Feb. 23, 2026 -- ZEISS Medical Technology, one of the world's leading medical technology companies, today launched its ZEISS Collaborative Care browser-based software application enabling eye care pr
- 김갑성 기자
- 2026-02-23 22:00
"Would You Clone Yourself for a Cure?" Clonell Unveils White Pa…

Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 -- Human cloning has long been a subject of dystopian science fiction and a stringent ethical taboo. However, Clonell Therapeutics, Inc., a cutting-edge biotechnology company, is actively shaking the landscape of regenerative medicine by bringing this powerful, historically controversial technology into the clinical setting in
- 김갑성 기자
- 2026-02-23 21:40
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase II…

CHENGDU, China, Feb. 23, 2026 -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the company's "AI + Chemical Induction" platform saw its first U.S. patient dosed for Parkinson's disease at Weill Cornell Medical Center and its first patient enrolled for Multiple System Atrophy (MSA) at Beijing Tiantan Hospital. These parallel milestones for NouvNeu001 and NouvNeu004 represent the next phase of iRegene's global strategy, transitioning from
- 김갑성 기자
- 2026-02-23 21:00
Formosa Pharmaceuticals Announces Licensing Agreeme…

TAIPEI, Feb. 23, 2026 -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), an innovative topical eyedrop for the treatment of inflammation and pain following ocular surgery in Australia and New Zealand. Arrotex, 'Australia's Medicines Company', currently fulfills 50% of the country's total volume and is a leader in
- 김갑성 기자
- 2026-02-23 14:00
Herbalife Announces Cristiano Ronaldo Invests $7.5 Million in…

Long-time partner invests in shared vision for personalized health and wellness HONG KONG, Feb. 23, 2026 -- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, announced global sports icon Cristiano Ronaldo acquired a 10% equity interest in HBL Pro2col Software, LLC, an indirect wholly-owned subsidiary of Herbalife that holds the Pro2col technology. Pro2col is Herbalife's next-generation, digital, personalized health and wellness operating system, designed to drive daily engagement, sustainable behavior change, and measurable outcomes thro
- 김갑성 기자
- 2026-02-23 12:00
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic T…

BANGKOK, Feb. 23, 2026 -- With a remarkable 30% growth in size and participation, Vitafoods Asia 2026 organised by Informa Markets, is set to redefine the nutraceutical industry in Asia, offering unparalleled opportunities for innovation and collaboration. The event will feature an exhibit space of 30,000 square meters with over 800 companies, representing an impressive 30% growth compared to the 2025 edition. Taking place once again at the state-of-the-art venue in Bangkok – Queen Sirikit National Convention Center (QSNCC) from 2 – 4 September 2026. New Country Pavilio
- 김갑성 기자
- 2026-02-23 10:09
CStone Announces MHRA Approval in UK for Sugemalimab in S…

[ 메디채널 김갑성 기자 ] Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. This approval is based on the GEMSTONE-301 study, a multicenter, randomized, double-blind Phase III trial. Results demonstrated that sugemalimab provided statistically significant improvement in progression-free survival (PFS) and a clinically meaningful prolongation of overall survival
- 김갑성 기자
- 2026-02-23 08:10
NYSE Content Update: Starfighters Space Celebrates NYSE Ame…

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 20, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Herbalife CFO joins Live after shares jump 18% Ashley Mastronardi delivers the pre-market update on February 20th Investors digest a pair of key reports from the U.S. Bureau of Economic Analysis, including the December PCE Report, the Fed's preferred inflation gauge
- 김갑성 기자
- 2026-02-20 22:28
HeyGears Announces One-Piece Denture Solution - Redefin…

[ 메디채널 김갑성 기자 ] HeyGears' One-Piece Denture Solution enables dual-material denture DLP 3D printing, seamlessly fusing denture base and teeth materials in a single printing process to deliver more natural aesthetics and a comfortable fit. CHICAGO, Feb. 20, 2026 -- HeyGears announces breakthrough One-Piece Denture Solution at LMT LAB DAY Chicago. [ 메디채널 김갑성 기자 ] HeyGears' One-Piece Denture Solution breaks through the technological constraints and experiential barriers of traditional denture manufacturing by deeply integrating HeyGears' new UltraCraft MMF (Mu
- 김갑성 기자
- 2026-02-20 22:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-02-24_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 02월 24일 13시 00분